249 related articles for article (PubMed ID: 12597315)
1. Celecoxib-induced upper gastrointestinal hemorrhage and ulceration.
Crawford AS; White JG
South Med J; 2002 Dec; 95(12):1444-6. PubMed ID: 12597315
[TBL] [Abstract][Full Text] [Related]
2. Celecoxib plus aspirin versus naproxen and lansoprazole plus aspirin: a randomized, double-blind, endoscopic trial.
Goldstein JL; Cryer B; Amer F; Hunt B
Clin Gastroenterol Hepatol; 2007 Oct; 5(10):1167-74. PubMed ID: 17916545
[TBL] [Abstract][Full Text] [Related]
3. [Gastroduodenal tolerance of celecoxib (celebrex) in patients with osteoarthrosis: an endoscopic evaluation].
Karateev AE
Ter Arkh; 2001; 73(5):63-4. PubMed ID: 11517755
[No Abstract] [Full Text] [Related]
4. Hospitalization for gastrointestinal bleeding associated with non-steroidal anti-inflammatory drugs among elderly patients using low-dose aspirin: a retrospective cohort study.
Rahme E; Bardou M; Dasgupta K; Toubouti Y; Ghosn J; Barkun AN
Rheumatology (Oxford); 2007 Feb; 46(2):265-72. PubMed ID: 16844699
[TBL] [Abstract][Full Text] [Related]
5. Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study.
Singh G; Fort JG; Goldstein JL; Levy RA; Hanrahan PS; Bello AE; Andrade-Ortega L; Wallemark C; Agrawal NM; Eisen GM; Stenson WF; Triadafilopoulos G;
Am J Med; 2006 Mar; 119(3):255-66. PubMed ID: 16490472
[TBL] [Abstract][Full Text] [Related]
6. COX-2 inhibitors and Celebrex: safe or suspect?
Health News; 1999 Jun; 5(7):4. PubMed ID: 10932776
[No Abstract] [Full Text] [Related]
7. [Celebrex: confirmed effectiveness and safety (new data)].
Nasonov EL
Ter Arkh; 2001; 73(5):57-61. PubMed ID: 11517753
[No Abstract] [Full Text] [Related]
8. Nonsteroidal anti-inflammatory drugs and lower gastrointestinal complications.
Lanas A; Sopeña F
Gastroenterol Clin North Am; 2009 Jun; 38(2):333-52. PubMed ID: 19446262
[TBL] [Abstract][Full Text] [Related]
9. [Gastrointestinal complications caused by NSAIDs. Over 60% of arthrosis patients are endangered].
MMW Fortschr Med; 2003 Mar; 145(10):60. PubMed ID: 12688036
[No Abstract] [Full Text] [Related]
10. Risk of gastrointestinal effects with COX-2 inhibitors and NSAIDs: what does evidence from randomised trials show about celecoxib?
Underhill JL
BMJ; 2005 Dec; 331(7530):1474-5. PubMed ID: 16356996
[No Abstract] [Full Text] [Related]
11. Meta-analysis: upper gastrointestinal tolerability of valdecoxib, a cyclooxygenase-2-specific inhibitor, compared with nonspecific nonsteroidal anti-inflammatory drugs among patients with osteoarthritis and rheumatoid arthritis.
Eisen GM; Goldstein JL; Hanna DB; Rublee DA
Aliment Pharmacol Ther; 2005 Mar; 21(5):591-8. PubMed ID: 15740543
[TBL] [Abstract][Full Text] [Related]
12. Risk of gastrointestinal effects with COX-2 inhibitors and NSAIDs: study conclusions do not reflect findings for celecoxib.
Feczko J
BMJ; 2005 Dec; 331(7530):1473-4. PubMed ID: 16356991
[No Abstract] [Full Text] [Related]
13. [COX-2 inhibitors: a new treatment in rheumatic diseases].
Puddu G; Cravero E
Clin Ter; 2003; 154(1):39-43. PubMed ID: 12854282
[TBL] [Abstract][Full Text] [Related]
14. The impact of low-dose aspirin on endoscopic gastric and duodenal ulcer rates in users of a non-selective non-steroidal anti-inflammatory drug or a cyclo-oxygenase-2-selective inhibitor.
Goldstein JL; Lowry SC; Lanza FL; Schwartz HI; Dodge WE
Aliment Pharmacol Ther; 2006 May; 23(10):1489-98. PubMed ID: 16669964
[TBL] [Abstract][Full Text] [Related]
15. Risk of upper gastrointestinal hemorrhage in warfarin users treated with nonselective NSAIDs or COX-2 inhibitors.
Battistella M; Mamdami MM; Juurlink DN; Rabeneck L; Laupacis A
Arch Intern Med; 2005 Jan; 165(2):189-92. PubMed ID: 15668365
[TBL] [Abstract][Full Text] [Related]
16. [Gastrointestinal damage induced by celecoxib and rofecoxib in rats].
Laudanno OM; Cesolari JA; Esnarriaga J; Rista L; Piombo G; Maglione C; Aramberry LJ; Sambrano JS; Godoy A; Rocaspana A
Acta Gastroenterol Latinoam; 2000; 30(1):27-33. PubMed ID: 10855352
[TBL] [Abstract][Full Text] [Related]
17. [Celecoxib and the CLASS study--worse and worse...].
Slørdal L
Tidsskr Nor Laegeforen; 2002 Sep; 122(22):2219. PubMed ID: 12426903
[No Abstract] [Full Text] [Related]
18. The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis.
Maetzel A; Krahn M; Naglie G
Arthritis Rheum; 2003 Jun; 49(3):283-92. PubMed ID: 12794781
[TBL] [Abstract][Full Text] [Related]
19. The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus.
Sowers JR; White WB; Pitt B; Whelton A; Simon LS; Winer N; Kivitz A; van Ingen H; Brabant T; Fort JG;
Arch Intern Med; 2005 Jan; 165(2):161-8. PubMed ID: 15668361
[TBL] [Abstract][Full Text] [Related]
20. [Safety of selective inhibitors of inducible cyclooxygenase-2 taken for a long period].
Lamarque D
Bull Cancer; 2004 May; 91 Spec No():S117-24. PubMed ID: 15239340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
